Hutchmed Share News (HCM)

Hutchmed gets Chinese approval for fruquintinib new drug application

(Alliance News) - Hutchmed (China) Ltd on Tuesday said the China National Medical Products Administration accepted its new drug application for fruquintinib in combination with paclitaxel.

Hutchmed to start registration phase enrolments for two treatments

(Alliance News) - Hutchmed China Ltd on Tuesday said it will start registration phase enrolments for two of its prospective treatments under study, HMPL-453 and savolitinib.

Hutchmed completes rolling FDA submission for colorectal cancer drug

(Sharecast News) - Pharmaceuticals developer Hutchmed China announced the completion of its rolling submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for its oral inhibitor 'fruquintinib'.

Hutchmed submits new drug application to US FDA for cancer treatment

(Alliance News) - Hutchmed (China) Ltd on Friday said it has completed the rolling submission of a new drug application for its fruquintinib cancer drug to the US Food & Drug Administration.

Hutchmed China inks global licensing deal with Takeda on fruquintinib

(Alliance News) - Hutchmed China Ltd on Tuesday said it closed a license agreement with a subsidiary of Tokyo-based drug maker Takeda Pharmaceutical Co Ltd for fruquintinib.

DIRECTOR DEALINGS: Hutchmed CFO banks GBP4 million; Haleon chair buys

(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Tuesday and Wednesday and not separately reported by Alliance News:

Hutchmed expects revenue climb from oncology, immunology division

(Alliance News) - Hutchmed (China) Ltd expects a sharp rise in revenue from its oncology and immunology-focused arm, as the biopharmaceutical firm looks forward to a productive 2023.

Hutchmed enrols last patient in lymphoma treatment trial

(Sharecast News) - Hutchmed China announced the completion of patient enrollment in a phase two registration trial of 'amdizalisib' on Monday, for the treatment of relapsed or refractory follicular lymphoma (FL), which is a subtype of non-Hodgkin's lymphoma.

Hutchmed completes patient enrolment for trial testing cancer therapy

(Alliance News) - Hutchmed (China) Ltd on Monday said that it has completed patient enrolment for the Phase Two registration trial of amdizalisib, its once-a-day oral monotherapy in patients with relapsed or refractory follicular lymphoma.

UK earnings, trading statements calendar - next 7 days

Hutchmed signs drug licensing deal with Takeda for sales outside China

(Alliance News) - Hutchmed (China) Ltd on Monday said it has signed an licensing agreement with Takeda Pharmaceutical Co Ltd for the Japanese company to commercialise Hutchmed's key cancer drug outside China.

TRADING UPDATES: Galileo confirms gold zone; Spectral hails results

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Hutchmed China completes enrolment for solveplenib clinical trial

(Sharecast News) - Hutchmed China announced on Tuesday that it has completed patient enrollment for 'ESLIM-01', a pivotal phase 3 clinical trial of sovleplenib for the treatment of adult patients with primary immune thrombocytopenia (ITP) in China.

Hutchmed completes patient enrolment for ITP clinical trial in China

(Alliance News) - Hutchmed (China) Ltd on Tuesday said it has completed patient enrolment for its clinical trial exploring potential treatment therapies for adults with primary immune thrombocytopenia in China.

TRADING UPDATES: Tekcapital's MicroSalt plans IPO in 2023

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: